The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
• 15 Jan 2019
Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Paris, France, shares his highlights for multiple myeloma (MM) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Prof. Mohty discusses advancements offering a promising outlook for MM patients, including BiTEs, CAR T-cell therapies, and daratumumab.
